Biotech company Enthera Pharmaceuticals has started a clinical trial to evaluate its product, Ent001, is safe and tolerated. This will lay the groundwork for the evaluation of the use of Ent001 in patients with inflammatory bowel disease and Type 1 diabetes. Ent001 is an antibody designed to target the pathway which plays a critical role in inflammatory bowel disease (IBD) and Type 1 diabetes (T1D), since Ent001 is designed to prevent cell death and inflammation underlying these diseases.
To read more, CLICK HERE.